R134
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 121
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.490
- INFLAMMATORY_RESPONSE+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- COMPLEMENT+0.370
- IL2_STAT5_SIGNALING+0.360
- KRAS_SIGNALING_UP+0.310
- TNFA_SIGNALING_VIA_NFKB+0.300
- HEME_METABOLISM+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- MYC_TARGETS_V1-0.410
- OXIDATIVE_PHOSPHORYLATION-0.300
- ANGIOGENESIS-0.290
- ADIPOGENESIS-0.270
- PEROXISOME-0.230
- XENOBIOTIC_METABOLISM-0.220
- E2F_TARGETS-0.210
- FATTY_ACID_METABOLISM-0.200
- BILE_ACID_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3MYEMXPQ | Med | Medulloblastoma | 0.848 |
| 2 | SRR8518454 | — | D | 0.837 |
| 3 | SRR8613774 | — | D | 0.824 |
| 4 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.824 |
| 5 | C3N-03765 | — | cohortA1 | 0.823 |
| 6 | TCGA-E9-A1NE-01A-21R-A14M-07 | — | A | 0.817 |
| 7 | SRR10900571 | — | — | 0.816 |
| 8 | SRR26320072 | — | — | 0.810 |
| 9 | SRR5088852 | — | — | 0.810 |
| 10 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |